Company intelligence / Profile preview

Gateway Biotechnology Inc.

Durham, North Carolina, United Statesgatewaybiotechnology.net ↗

Ownership: Private
Employees: ~1
Development stage: Preclinical

Overview

The company has developed a novel animal screening model for tinnitus and has identified promising drug candidates (GW-TT2 and GW-TT5) for clinical studies. Their lead product is reportedly undergoing a Phase II clinical trial as part of an exclusive contract with the U.S. Army.

Therapeutic areas: Neurology
Modalities: Small moleculesDrug therapies
Industry: Biotech

Drug pipeline

4 assets

GW-TT3

Preclinical

3 more assets in the full pipeline.

Request access →

Partnerships

U.S. Army (exclusive contract)

Beyond the preview

Go deeper on Gateway Biotechnology Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gateway Biotechnology Inc..

Explore the full profile